載入...
Single or combined immune checkpoint inhibitors compared to first‐line platinum‐based chemotherapy with or without bevacizumab for people with advanced non‐small cell lung cancer
BACKGROUND: Immune checkpoint inhibitors (ICIs) targeting the PD‐1/PD‐L1 axis have changed the first‐line treatment of people with advanced non‐small cell lung cancer (NSCLC). Single‐agent pembrolizumab (a PD‐1 inhibitor) is currently the standard of care as monotherapy in patients with PD‐L1 expres...
Na minha lista:
| 發表在: | Cochrane Database Syst Rev |
|---|---|
| Main Authors: | , , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
John Wiley & Sons, Ltd
2020
|
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8094159/ https://ncbi.nlm.nih.gov/pubmed/33316104 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/14651858.CD013257.pub2 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|